Pro-tumor activities of macrophages in the progression of melanoma

References

• Organization WH. World cancer report, 2014. WHO Report. Geneva: WHO; 2014; Chapter 5.14.
   Google Scholar
• committee; Cme. China's guidelines of diagnosis and treatment of melanoma (2011). Chinese Clin Oncol 2012(02):159-71.
   Google Scholar
• Han Y, Qu X. The current situations and advances in cutaneous malignant melanoma. Modern J Integrated Traditional Chinese Western Med 2015(30):3416-20.
   Google Scholar
• Kaufmann SH. Elie Metchnikoff's and Paul Ehrlich's impact on infection biology. Microbes Infect 2008; 10(14):1417-9; PMID:18824243; https://doi.org/10.1016/j.micinf.2008.08.012
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8(12):958-69; PMID:19029990; https://doi.org/10.1038/nri2448
   PubMed Web of Science ®Google Scholar
• Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002; 19(3):247-58; PMID:12067205; https://doi.org/10.1023/A:1015587423262
   PubMed Web of Science ®Google Scholar
• Kozłowska K, Cichorek M. Heterogeneity of peritoneal macrophages in hamsters-bearing transplantable melanomas in relation to their transglutaminase. Folia Histochem Cytobiol 1990; 29(4):141-7.
   Web of Science ®Google Scholar
• Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164(12):6166-73; PMID:10843666; https://doi.org/10.4049/jimmunol.164.12.6166
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41(1):14-20; PMID:25035950; https://doi.org/10.1016/j.immuni.2014.06.008
   PubMed Web of Science ®Google Scholar
• Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in Immunopathology 2013; 35(5): 585-600.
   Google Scholar
• Wang H, Zhang L, Yang L, Liu C, Zhang Q, Zhang L. Targeting macrophage anti-tumor activity to suppress melanoma progression. Oncotarget 2017; 8(11):18486-96.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004; 14(3): 155-60.
   Google Scholar
• Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008; 365(2):279-84; PMID:17991428; https://doi.org/10.1016/j.bbrc.2007.10.182
   PubMed Web of Science ®Google Scholar
• Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007; 127(8):2031-41; PMID:17460736; https://doi.org/10.1038/sj.jid.5700827
   PubMed Web of Science ®Google Scholar
• Eubank T, Bailey M, Gross A, Sumner L, Marsh C, Glaser R, Yang E. 7. CCL2 down-regulation from macrophages by stress-induced β-adrenergic receptor activation is protective in a model of malignant melanoma. Brain Behavior Immunity 2011; 25:S180-1; https://doi.org/10.1016/j.bbi.2011.07.010
   Google Scholar
• Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166(11):6483-90; PMID:11359798; https://doi.org/10.4049/jimmunol.166.11.6483
   PubMed Web of Science ®Google Scholar
• Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153(1):103-8; PMID:9665470; https://doi.org/10.1016/S0002-9440(10)65550-2
   PubMed Web of Science ®Google Scholar
• Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159(3):893-903; PMID:11549582; https://doi.org/10.1016/S0002-9440(10)61765-8
   PubMed Web of Science ®Google Scholar
• Marquardt H, Todaro GJ. Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterization. J Biol Chem 1982; 257(9):5220-5.
   PubMed Web of Science ®Google Scholar
• Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12(6):547-54; PMID:10843728; https://doi.org/10.1006/cyto.1999.0614
   PubMed Web of Science ®Google Scholar
• Krasagakis K, Krüger‐Krasagakes S, Fimmel S, Eberle J, Thölke D, Von Der Ohe M, Mansmann U, Orfanos CE. Desensitization of melanoma cells to autocrine TGF‐β isoforms. J Cell Physiol 1999; 178(2):179-87; PMID:10048582; https://doi.org/10.1002/(SICI)1097-4652(199902)178:2%3c179::AID-JCP7%3e3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 1994; 145(1):97; PMID:8030760
   PubMed Web of Science ®Google Scholar
• Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996; 148(6):1887; PMID:8669474
   PubMed Web of Science ®Google Scholar
• Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali U, Giannotti B. In situ expression of transforming growth factor [beta] is associated with melanoma progression and correlates with Ki67, HLA-DR and [beta] 3 integrin expression. Melanoma Res 1997; 7(4):313-21; PMID:9293481; https://doi.org/10.1097/00008390-199708000-00006
   PubMed Web of Science ®Google Scholar
• Hazelbag S, Fleuren GJ, Baelde J, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecologic Oncol 2001; 83(2):235-43; PMID:11606077; https://doi.org/10.1006/gyno.2001.6378
   PubMed Web of Science ®Google Scholar
• Ortegel JW, Staren ED, Faber L, Warren WH, Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 2002; 36(1):17-25; PMID:11891029; https://doi.org/10.1016/S0169-5002(01)00472-X
   PubMed Web of Science ®Google Scholar
• Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin‐4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type‐2 macrophages. Scandinavian J Immunol 2005; 61(1):10-7; PMID:15644118; https://doi.org/10.1111/j.0300-9475.2005.01524.x
   PubMed Web of Science ®Google Scholar
• Gratchev A, Kzhyshkowska J, Kannookadan S, Ochsenreiter M, Popova A, Yu X, Mamidi S, Stonehouse-Usselmann E, Muller-Molinet I, Gooi L. Activation of a TGF-β-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-β receptor II. J Immunol 2008; 180(10):6553-65; PMID:18453574; https://doi.org/10.4049/jimmunol.180.10.6553
   PubMed Web of Science ®Google Scholar
• Vodovotz Y, Bogdan C, Paik J, Xie Q, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 1993; 178(2):605-13; PMID:7688028; https://doi.org/10.1084/jem.178.2.605
   PubMed Web of Science ®Google Scholar
• Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M. Transforming growth factor-β1 increases survival of human melanoma through stroma remodeling. Cancer Res 2001; 61(22):8306-16; PMID:11719464
   PubMed Web of Science ®Google Scholar
• Ma D, Niederkorn J. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 1995; 86(2):263; PMID:7490128
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, Te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, De Vries JE. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174(4):915-24; PMID:1655948; https://doi.org/10.1084/jem.174.4.915
   PubMed Web of Science ®Google Scholar
• Ding L, Linsley P, Huang L, Germain R, Shevach E. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151(3):1224-34; PMID:7687627
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146(10):3444-51; PMID:1827484
   PubMed Web of Science ®Google Scholar
• Chen Q, Daniel V, Maher DW, Hersey P. Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56(5):755-60; PMID:8314354; https://doi.org/10.1002/ijc.2910560524
   PubMed Web of Science ®Google Scholar
• Liu C-Y, Xu J-Y, Shi X-Y, Huang W, Ruan T-Y, Xie P, Ding J-L. M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 2013; 93(7):844-54; PMID:23752129; https://doi.org/10.1038/labinvest.2013.69
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev™ Neurobiol 1997; 11(2–3):167-239
   PubMedGoogle Scholar
• Zudaire E, Martınez A, Cuttitta F. Adrenomedullin and cancer. Regulatory Peptides 2003; 112(1):175-83; PMID:12667640; https://doi.org/10.1016/S0167-0115(03)00037-5
   PubMedGoogle Scholar
• Nikitenko L, Fox S, Kehoe S, Rees M, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006; 94(1):1-7; PMID:16251875; https://doi.org/10.1038/sj.bjc.6602832
   PubMed Web of Science ®Google Scholar
• MartÍnez A, Elsasser TH, Muro-Cacho C, Moody TW, Miller MJ, Macri CJ, Cuttitta F. Expression of adrenomedullin and its receptor in normal and malignant human skin: a potential pluripotent role in the integument. Endocrinology 1997; 138(12):5597-604; https://doi.org/10.1210/endo.138.12.5622
   PubMed Web of Science ®Google Scholar
• Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res 2011; 17(23):7230-9; PMID:21994414; https://doi.org/10.1158/1078-0432.CCR-11-1354
   PubMed Web of Science ®Google Scholar
• den Breems NY, Eftimie R. The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes. J Theoretical Biol 2016; 390:23-39; PMID:26551154; https://doi.org/10.1016/j.jtbi.2015.10.034
   PubMed Web of Science ®Google Scholar
• Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 2006; 16(3):213-22; PMID:16718268; https://doi.org/10.1097/01.cmr.0000215030.69823.11
   PubMed Web of Science ®Google Scholar
• Koszalka P, Golunska M, Stanislawowski M, Urban A, Stasilojc G, Majewski M, Wierzbicki P, Skladanowski AC, Bigda J. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis. Int J Biochem Cell Biol 2015; 69:1-10; PMID:26545615; https://doi.org/10.1016/j.biocel.2015.10.003
   PubMed Web of Science ®Google Scholar
• Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemela J, Laurila JP, Elima K, Jalkanen S, Salmi M. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41(5):1231-41; PMID:21469131; https://doi.org/10.1002/eji.201041292
   PubMed Web of Science ®Google Scholar
• Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I, Kaszewski W, Michalkiewicz J, Zegarski W. Collaborating with the enemy: function of macrophages in the development of neoplastic disease. Mediators Inflamm 2013; 2013:831387; PMID:23576856; https://doi.org/10.1155/2013/831387
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11(10):889-96; PMID:20856220; https://doi.org/10.1038/ni.1937
   PubMed Web of Science ®Google Scholar
• Massi D, Marconi C, Franchi A, Bianchini F, Paglierani M, Ketabchi S, Miracco C, Santucci M, Calorini L. Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors. Hum Pathol 2007; 38(10):1516-25; PMID:17640716; https://doi.org/10.1016/j.humpath.2007.02.018
   PubMed Web of Science ®Google Scholar
• Gal A, Tapmeier T, Balathasan L, Muschel R. 304 Myeloid response and macrophage polarization in mouse melanoma lung metastasis. European J Cancer Supplements 2010; 8(5):78-9; https://doi.org/10.1016/S1359-6349(10)71108-3
   Google Scholar
• Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Different 2008; 15(1):80-8; https://doi.org/10.1038/sj.cdd.4402237
   PubMed Web of Science ®Google Scholar
• Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011; 71(11):3792-801; PMID:21478294; https://doi.org/10.1158/0008-5472.CAN-10-4455
   PubMed Web of Science ®Google Scholar
• Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K, Szegletes Z, Varo G, Siklos L, Katona RL. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Letters 2012; 148(1):34-8; PMID:22898052; https://doi.org/10.1016/j.imlet.2012.07.006
   PubMed Web of Science ®Google Scholar
• Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, Ottenhoff TH. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFβ-1. J Immunol 2008; 181(3):2220-6; PMID:18641362; https://doi.org/10.4049/jimmunol.181.3.2220
   PubMed Web of Science ®Google Scholar
• Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf D, Umansky V. Skin melanoma development in ret transgenic mice despite the depletion of CD25+ Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009; 183(10):6330-7; PMID:19841169; https://doi.org/10.4049/jimmunol.0900609
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Petersson M, Höglund P, Kiessling R, Klein G, Kärre K. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci 1987; 84(10):3405-9; https://doi.org/10.1073/pnas.84.10.3405
   PubMed Web of Science ®Google Scholar
• Garbe C, Krasagakis K, Zouboulis CC, Schröder K, Krüger S, Stadler R, Orfanos CE. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 1990; 95:231S-7S; https://doi.org/10.1111/1523-1747.ep12875837
   PubMed Web of Science ®Google Scholar
• Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001; 8(2):116-22; PMID:11258775; https://doi.org/10.1007/s10434-001-0116-3
   PubMed Web of Science ®Google Scholar
• Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995; 87(22):1710-3; PMID:7473820; https://doi.org/10.1093/jnci/87.22.1710
   PubMedGoogle Scholar
• Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, Feigenbaum L, Fuchs E, Lyakh L, Young HA. Interferon-[ggr] links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469(7331):548-53; PMID:21248750; https://doi.org/10.1038/nature09666
   PubMed Web of Science ®Google Scholar
• Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74–MIF Interactions Drive Melanoma survival in response to Interferon-γ. J Invest Dermatol 2015; 135(11):2901.
   PubMed Web of Science ®Google Scholar
• Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T. Upregulation of renin‐angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17(4):537-45; PMID:10404956; https://doi.org/10.1097/00004872-199917040-00012
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, Kuswanto W, Rauch PJ, Chudnovskiy A, Iwamoto Y. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013; 38(2):296-308; PMID:23333075; https://doi.org/10.1016/j.immuni.2012.10.015
   PubMed Web of Science ®Google Scholar
• Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JA, Williams IR, Capecchi MR, Taylor WR, Bernstein KE. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol 2007; 170(6):2122-34; PMID:17525278; https://doi.org/10.2353/ajpath.2007.061205
   PubMed Web of Science ®Google Scholar
• Egami K, Murohara T, Shimada T, Sasaki K-i, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112(1):67-75; PMID:12840060; https://doi.org/10.1172/JCI16645
   PubMed Web of Science ®Google Scholar
• Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M, Mannini A, Mugnai G, Calorini L. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat 2007; 83(4):320-8; https://doi.org/10.1016/j.prostaglandins.2007.03.003
   PubMed Web of Science ®Google Scholar
• Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243(1):136-51; PMID:21884173; https://doi.org/10.1111/j.1600-065X.2011.01046.x
   PubMed Web of Science ®Google Scholar
• Elaraj D, Weinreich D, Varghese S, Puhlmann M, Hewitt S, Carroll N, Feldman E, Turner E, Alexander H. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006; 12(4):1088-96; PMID:16489061; https://doi.org/10.1158/1078-0432.CCR-05-1603
   PubMed Web of Science ®Google Scholar
• Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, Cheng P, Dummer R, Kerl K, Contassot E. Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages. J Dermatol Sci 2014; 74(2):167-9; PMID:24581590; https://doi.org/10.1016/j.jdermsci.2014.01.006
   PubMed Web of Science ®Google Scholar
• Björkdahl O, Wingren A, Hedhund G, Ohlsson L, Dohlsten M. Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo. Cancer Immunol Immunother 1997; 44(5):273-81; PMID:9247562; https://doi.org/10.1007/s002620050383
   PubMed Web of Science ®Google Scholar
• Pawelek JM. Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease in cancer. Chin J Cancer 2014; 33(3):133-9; PMID:24589183; https://doi.org/10.5732/cjc.013.10243
   PubMed Web of Science ®Google Scholar
• Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes D, Pawelek J. Melanoma × macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis 1998; 16(4):299-312; https://doi.org/10.1023/A:1006557228604
   PubMed Web of Science ®Google Scholar
• Rachkovsky M, Pawelek J. Acquired Melanocyte Stimulating Hormone-inducible Chemotaxis following Macrophage Fusion with Cloudman S91 Melanoma cells. Cell Growth Differ 1999; 10(7):517-24.
   PubMedGoogle Scholar
• Chakraborty AK, Pawelek J. Beta1,6-branched oligosaccharides regulate melanin content and motility in macrophage-melanoma fusion hybrids. Melanoma Res 2007; 17(1):9-16; PMID:17235237; https://doi.org/10.1097/CMR.0b013e3280114f34
   PubMed Web of Science ®Google Scholar
• Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res 2005; 11(8):2969-73; PMID:15837749; https://doi.org/10.1158/1078-0432.CCR-04-2211
   PubMed Web of Science ®Google Scholar